First Tracks Biotherapeutics/$TRAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About First Tracks Biotherapeutics
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Ticker
$TRAX
Sector
Primary listing
Employees
104
Headquarters
Website
TRAX Metrics
BasicAdvanced
$624m
-
-$4.85
-
-
Price and volume
Market cap
$624m
52-week high
$25.58
52-week low
$14.72
Average daily volume
480k
Financial strength
Current ratio
8.74
Quick ratio
8.651
Profitability
EBITDA (TTM)
-179.999
Management effectiveness
Valuation
Price to book
2.42
Price to tangible book (TTM)
2.42
Price to free cash flow (TTM)
-4.779
Free cash flow yield (TTM)
-20.93%
Free cash flow per share (TTM)
-3.742
Growth
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs